Anthropic’s AI Claude discovers new enzyme system akin to CRISPR

Anthropic says its AI model Claude has “autonomously discovered” a novel enzyme system that resembles the molecular machinery behind CRISPR, the gene-editing technology that reshaped modern biology. The discovery emerged from Claude sifting through a massive database of DNA sequences, with Anthropic claiming its human scientists’ involvement was limited to writing the initial prompt and handling the physical lab work.

From silicon to petri dishes

The enzyme discovery is the first published result from Anthropic’s newly launched wet lab in the San Francisco Bay Area, which the company officially confirmed on September 18, 2026. The facility was designed to close the loop between AI-generated hypotheses and physical biological experiments, giving Claude a way to have its computational predictions tested against reality.

On June 30, 2026, the company launched Claude Science, a specialized platform integrating over 60 scientific databases to streamline workflows in protein design, genomics, and related fields.

Early results from August 2026 suggest Claude’s protein design capabilities are already outpacing industry norms. The company reports that its Claude models achieved hit rates of 22-35% for protein design, roughly double the typical industry benchmark of 10-15%. In practical terms, Claude designed 1,320 proteins, and 354 of them were confirmed as functional binders across 15 different targets.

What Claude actually found

Claude’s approach, according to Anthropic, involved searching through enormous genomic databases to identify enzyme systems that had been overlooked by human researchers. The AI wasn’t told what to look for beyond the initial prompt. It identified patterns in DNA sequences that pointed to a previously uncharacterized system with functional similarities to CRISPR’s molecular toolkit.

Anthropic’s scientists still had to do the lab work to confirm the enzyme system actually functions as Claude predicted. The wet lab exists precisely because in silico predictions need in vitro confirmation.

The business angle

Anthropic’s wet lab operates on a hybrid model, conducting some experiments in-house while partnering with external organizations for others. The company has positioned itself as a research and platform partner for pharmaceutical companies rather than a drug developer itself, deliberately avoiding clinical-stage development.

The models involved in the protein design work, identified as Opus 4.8 and Mythos Preview, suggest Anthropic is developing specialized scientific variants of Claude rather than relying solely on its general-purpose models.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.